Illumina, Inc. (ILMN)
$
117.67
-2.33 (-1.98%)
Key metrics
Financial statements
Free cash flow per share
6.1373
Market cap
17.8 Billion
Price to sales ratio
4.1028
Debt to equity
0.9604
Current ratio
2.0751
Income quality
1.0790
Average inventory
577 Million
ROE
0.3370
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis, reflecting its robust operational framework. The earnings per share (EPS) is reported at $5.47 indicating the company's profitability on a per-share basis, while the net total of other income and expenses is $221,000,000.00 reflecting non-core financial activities. Operating expenses amount to $2,022,000,000.00 encompassing various operational costs incurred, and the total costs and expenses for the company are $3,477,000,000.00 reflecting its overall spending. Additionally, the weighted average number of shares outstanding is $153,000,000.00 highlighting the company's shareholder base and underscoring its financial health and stability. With a diverse range of products and services, Illumina serves a broad set of customers in genomic research centers, academic institutions, government laboratories, hospitals, and commercial entities in the pharmaceutical, biotechnology, and molecular diagnostics sectors. The company was incorporated in 1998 and is headquartered in San Diego, California, ensuring a strong presence in crucial markets. The stock is reasonably priced at $102.75 appealing to a broad range of investors looking for opportunities in the biotech field. Furthermore, the stock has a high average trading volume of $1,934,815.00 indicating strong liquidity and investor interest. With a mid-range market capitalization of $17,991,743,000.00 the company is a steady performer in the market. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape and driving advances in genetic analysis technologies. Additionally, it belongs to the Healthcare sector, which is experiencing rapid growth and innovation, positioning Illumina as a vital contributor to advancements in life sciences, oncology, and other emerging market segments.
Is Illumina, Inc. (ILMN) a good investment?
Investing in Illumina, Inc. (ILMN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.
What is Illumina, Inc. (ILMN)'s stock forecast?
Analysts predict Illumina, Inc. stock to fluctuate between $68.70 (low) and $155.53 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Illumina, Inc.'s market capitalization?
As of 2026-02-20, Illumina, Inc.'s market cap is $17,991,743,000, based on 152,900,000 outstanding shares.
How does Illumina, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Illumina, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Illumina, Inc. (ILMN) stock?
To buy Illumina, Inc. (ILMN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ILMN. Place an order (Market, Limit, etc.).
What is the best time to invest in Illumina, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Illumina, Inc. stock ever split?
Illumina, Inc.'s last stock split was 2:1 on 2008-09-23.
How did Illumina, Inc. perform in the last earnings report?
Revenue: $4,342,000,000 | EPS: $5.47 | Growth: -171.13%.
Where can I find Illumina, Inc.'s investor relations reports?
Visit https://www.illumina.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Illumina, Inc.?
You can explore historical data from here
What is the all-time high and low for Illumina, Inc. stock?
All-time high: $526 (2021-08-16) | All-time low: $68.70 (2025-04-09).
What are the key trends affecting Illumina, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
prnewswire.com
SAN DIEGO, Feb. 17, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference TD Cowen 46th Annual Health Care Conference 2026 on March 3, 2026 The fireside chat is scheduled for 12:10pm PT (3:10pm ET). The webcast can be accessed through the Events & Presentations section of Illumina's website at investor.illumina.com.
zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com
ILMN tops Q4 EPS and revenue estimates, posts 42% profit jump, but shares slide 10% on margin concerns despite 2026 growth outlook.
seekingalpha.com
Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript
zacks.com
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Illumina (ILMN) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $0.86 per share a year ago.
zacks.com
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
prnewswire.com
Illumina will sequence up to 4,000 unique individual animals across 1,300 species, unlock genomic insights from 50-year-old biological samples Sequencing connects decades of preserved biodiversity with the latest multiomic technologies SAN DIEGO, Feb. 3, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a sequencing agreement with the San Diego Zoo Wildlife Alliance (SDZWA)'s Frozen Zoo®. The 50-year-old biobank is the world's most comprehensive and diverse collection of living cells from threatened and endangered species across the animal kingdom.
zacks.com
Illumina eyes Q4 growth on NovaSeq X momentum, new multiomic launches and stronger sequencing demand despite China export limits.
See all news
